ArticleClinical cancer research : an official journal of the American Association for Cancer Research2023

Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma.

Srivandana Akshintala et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.